Key findings for this group:People with a specific high‑risk Alzheimer’s gene (APOE ε4 homozygotes) were about four times more likely to develop ARIA. The study also found that seven commonly available clinical, blood and imaging tests – either alone or combined – could not yet reliably predict who would develop ARIA. “The decision of whether or not these new medications are right for you is highly individualized,” said Heather Whitson, M.D., co-author of the study and co-director of the Duke & UNC Alzheimer’s Disease Research Center. Sally Osmer didn’t hesitate when her doctors at Duke Health offered lecanemab as a treatment after she was diagnosed with early-stage Alzheimer’s disease at age 74. One or more study authors also have relationships with various pharmaceutical companies, including the maker of lecanemab.